Reviva Pharmaceuticals Holding - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
RVPH Nasdaq 8731 https://revivapharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Reviva Pharmaceuticals Holding

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - Oct 2nd, 2024 12:30 pm
Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference - Sep 26th, 2024 12:30 pm
RVPH: RECOVER Biomarker KOL Event - Sep 16th, 2024 3:43 pm
Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia - Sep 9th, 2024 12:00 pm
Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Sep 4th, 2024 12:00 pm
Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024 - Aug 27th, 2024 12:00 pm
RVPH: August OLE Update - Aug 26th, 2024 4:24 pm
Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules - Aug 21st, 2024 10:00 am
Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Aug 14th, 2024 12:00 pm
Reviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis - Aug 6th, 2024 12:00 pm
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension - Jul 9th, 2024 12:00 pm
Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - May 29th, 2024 8:45 pm
Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - May 28th, 2024 12:00 pm
RVPH: Enrollment Right Around the Corner - May 22nd, 2024 1:36 pm
Reviva to Participate in the BIO International Convention - May 21st, 2024 12:00 pm
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - May 15th, 2024 12:00 pm
Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights - May 14th, 2024 12:00 pm
Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference - May 13th, 2024 12:00 pm
Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting - May 9th, 2024 12:00 pm
RVPH: Full Year 2023 Results - Apr 25th, 2024 10:31 am